The Virtual Investor “What This Means” segment featuring Outlook Therapeutics is now available here.

Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® approved by Health Canada for both subcutaneous and intravenous ...

Received US Institutional Review Board (IRB) approval for pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) and engaged leading contract research organization (CRO); On track to begin ...

The dollar strengthens as strong U.S. data drives up yields, dampening expectations of Federal Reserve rate cuts. The yen weakens near levels that previously prompted intervention, and the euro and ...